# AstraZeneca advances three treatments across Cardiovascular, Cancer and Rare Diseases

- Link: https://www.directorstalkinterviews.com/astrazeneca-advances-three-treatments-across-cardiovascular-cancer-and-rare-diseases/4121269825
- Published: 2026-11-16T07:04:00+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Baxfendy_ (baxdrostat) has been recommended for approval in the European Union (
EU) for the treatment of adults with arterial hypertension insufficiently controlled
with at least two antihypertensive medicinal products. If approved, _Baxfendy_ will
be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting
aldosterone to address a key biological driver of elevated blood pressure.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) based its positive opinion on results from two pivotal Phase III trials
in which _Baxfendy_ demonstrated statistically significant and clinically meaningful
reductions in seated systolic blood pressure (SBP) in patients with uncontrolled
or resistant hypertension, and 24-hour average ambulatory SBP in patients with resistant
hypertension.^(1,2)

There are 1.4 billion people worldwide living with hypertension.^(3) Approximately
50% of people already taking two or more antihypertensive medications struggle with
persistently uncontrolled hypertension.^(4,5) About 70 million adults across Europe
have hypertension that remains uncontrolled despite treatment, putting them at increased
risk for cardiovascular disease and premature death.^(3,6,7) Hypertension is the
most prevalent and significant modifiable cardiovascular risk factor worldwide, 
accounting for more deaths and disability than any other modifiable risk.^(8-10)
Elevated aldosterone levels play a central role in persistently uncontrolled hypertension
and are associated with a decline in kidney function and increased cardiovascular
risk.^(11-13)

> **Dr. Bryan Williams, Chair of Medicine at University College London and primary
> investigator for BaxHTN and Bax24, said**: “The strength of the research behind
> _Baxfendy_ is a triumph of science and demonstrates its potential as an important
> new class of treatment for people in Europe living with persistently uncontrolled
> hypertension. Epidemiological data indicate that a 10 mmHg decrease in systolic
> blood pressure is associated with a roughly 20% lower risk of serious cardiovascular
> events like heart attack and stroke, underscoring why effective blood pressure
> lowering matters for people living with uncontrolled hypertension.”

> **Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business
> Unit, AstraZeneca, said**: “Hypertension is often called the ‘silent killer’ and
> is a leading risk factor for heart attack, stroke and dementia. This positive 
> CHMP opinion for _Baxfendy_ marks a significant step toward bringing this potential
> first-in-class innovation to patients in Europe. This novel medicine reflects 
> the strength of our pipeline across interconnected cardiovascular, renal and metabolic
> diseases as we deliver on our 2030 ambition to bring 20 new medicines to the world.”

In the BaxHTN Phase III trial,^(14) published in the New England Journal of Medicine,
^(1) _Baxfendy_ demonstrated statistically significant and clinically meaningful
efficacy for the treatment of patients with hypertension on top of standard of care.
At week 12, the absolute reduction from baseline in mean seated SBP was 15.7 mmHg(
95% confidence interval [CI], -17.6 to -13.7) and the placebo-adjusted reduction
was 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) for the 2mg dose.

In the Bax24 Phase III trial,^(15) published in The Lancet,^(2) _Baxfendy_ demonstrated
statistically significant, clinically meaningful and consistent blood pressure reductions
in patients with resistant hypertension who received baxdrostat 2mg or placebo on
top of standard of care. At week 12, the absolute reduction from baseline in ambulatory
24-hour average SBP was 16.6 mmHg (95% CI, -18.8 to -14.3) and the placebo-adjusted
reduction was 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001). Efficacy was observed 
throughout the 24-hour period, including early morning, when patients with hypertension
are at a higher risk of cardiovascular events.^(16,17)

_Baxfendy_ was generally well-tolerated in the trials, with no unanticipated safety
findings.

_Baxfendy_ is approved in the US and other countries as a first-in-class ASI for
adults with hypertension not adequately controlled on other therapies, with regulatory
filings currently under review in other major regions, including Japan and China.

_Baxfendy_ is a first-in-class, highly selective and potent ASI designed to lower
blood pressure in a new way by specifically inhibiting the production of aldosterone,
^(18) a hormone that raises blood pressure to unhealthy levels and increases the
risk of heart and kidney problems.^(11-13)

**AstraZeneca**’s _Imfinzi_ (durvalumab) in combination with enfortumab vedotin (
EV) as neoadjuvant treatment, followed by _Imfinzi_ monotherapy as adjuvant treatment
after radical cystectomy (surgery to remove the bladder), has been approved in the
US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC)
who are ineligible for or have refused cisplatin-based chemotherapy.

The approval was granted by the Food and Drug Administration after securing Priority
Review and was based on results from the VOLGA Phase III trial which were presented
during a Presidential Symposium at the 2026 European Society for Medical Oncology(
ESMO) Congress and simultaneously published in The New England Journal of Medicine.

In 2026, around 16,000 patients will be treated for MIBC in the United States.^(
1) Approximately one in four patients with bladder cancer has muscle-invasive disease,
where the tumour invades the muscle wall of the bladder, without distant metastases.
^(2,3) As many as 50% of patients are ineligible for cisplatin-based chemotherapy
due to impaired renal function or comorbidities.^(4,5) The standard treatment for
these patients has historically been radical cystectomy alone, but despite undergoing
this major surgery, patients experience high rates of recurrence and have a poor
prognosis.^(4-6)

> **Jonathan E. Rosenberg, MD, Chief of the Genitourinary Oncology Service at the
> Memorial Sloan Kettering Cancer Center and member of the VOLGA Steering Committee,
> said**: “This approval brings the first perioperative immunotherapy regimen where
> enfortumab vedotin is administered only in the neoadjuvant setting to patients
> with muscle-invasive bladder cancer who are not candidates for cisplatin-based
> chemotherapy. The results of VOLGA show a statistically significant and clinically
> meaningful improvement in both event-free and overall survival along with a manageable
> safety profile. Based on this, the VOLGA regimen has the potential to become a
> new standard of care in this curative-intent setting.”

> **Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit,
> AstraZeneca, said:** “Today’s approval offers a novel _Imfinzi_-based regimen 
> that almost halved the risk of disease recurrence and reduced the risk of death
> by 42 per cent in the VOLGA trial, allowing physicians to optimise treatment for
> patients in this curative-intent setting. As our third bladder cancer indication
> in two years, this approval reinforces _Imfinzi_ as an immunotherapy backbone 
> across muscle-invasive and non-muscle-invasive disease.”

In the trial, patients were treated with three cycles of _Imfinzi_ and EV before
radical cystectomy, followed by nine cycles of _Imfinzi_ adjuvant monotherapy. In
a planned interim analysis, perioperative _Imfinzi_ plus neoadjuvant EV demonstrated
a 49% reduction in the risk of disease progression, recurrence, not undergoing surgery
or death versus radical cystectomy with or without approved adjuvant treatment (
based on an event-free survival [EFS] hazard ratio [HR] of 0.51; 95% confidence 
interval [CI] 0.38-0.67; p<0.0001). Estimated median EFS was not yet reached for
the _Imfinzi_ combination versus 12.1 months for the comparator arm. An estimated
64% of patients treated with the _Imfinzi_ combination remained alive and event-
free at two years compared to 45% in the comparator arm.

Results from the key secondary endpoint of overall survival (OS) showed that the
_Imfinzi_ combination reduced the risk of death by 42% compared to the comparator
arm (based on an OS HR of 0.58; 95% CI 0.40-0.83; p=0.0027). Estimated median OS
was not yet reached for the _Imfinzi_ combination or comparator arm. An estimated
78% of patients treated with the _Imfinzi_ combination were alive at two years compared
to 69% in the comparator arm.  

The safety and tolerability of _Imfinzi_ plus EV was consistent with the known safety
profiles of the individual medicines, with no new safety signals identified. Grade
3 and 4 adverse events due to any cause occurred in 64% of patients treated with
the _Imfinzi_ combination and 44% of patients in the comparator arm. Patient-reported
quality of life was maintained after surgery in patients treated with the _Imfinzi_
combination.

Regulatory applications are currently under review in the European Union (EU), Japan
and several other countries based on the results of the VOLGA trial. 

_Imfinzi_ is approved in over 50 countries for patients with cisplatin-eligible MIBC
based on the NIAGARA Phase III trial. _Imfinzi_ in combination with Bacillus Calmette-
Guérin (BCG) induction and maintenance therapy is approved in the US, Japan and 
other countries for patients with BCG-naïve, high-risk non-muscle-invasive bladder
cancer, based on the POTOMAC Phase III trial. In July 2026, positive high-level 
results from the NILE Phase III trial showed _Imfinzi_ plus chemotherapy demonstrated
a statistically significant and clinically meaningful improvement in OS versus chemotherapy
as 1st-line treatment for patients with PD-L1 high unresectable, locally advanced
or metastatic urothelial cancer.

Alexion,** AstraZeneca** Rare Disease’s _Klygefa_ (gefurulimab) has been approved
in the European Union (EU) as an add-on to standard therapy for the treatment of
generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor(
AChR) antibody positive. _Klygefa_ is the first and only dual-binding nanobody C5
inhibitor, offering once-weekly subcutaneous self-administration via autoinjector.

The approval by the European Commission follows the positive opinion of the Committee
for Medicinal Products for Human Use of the European Medicines Agency and was based
on positive results from the pivotal PREVAIL Phase III trial. Results from the trial
showed that _Klygefa_ met its primary endpoint, demonstrating improvement from baseline
in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 
compared to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p<0.0001).
A clinically meaningful improvement was observed as early as week one, and was sustained
through week 26.^(1)

gMG is a rare autoimmune disorder characterised by reduced muscle function and severe
muscle weakness.^(2) An estimated 82,500 people are diagnosed with gMG in Europe
5 countries (Germany, France, UK, Italy and Spain) with approximately 66,000 being
AChR-positive.^(3)

Tobias Ruck, MD, Director Department of Neurology, BG University Hospital Bergmannsheil
Bochum, Ruhr-University Bochum and investigator in the trial, said: “Clinical management
of gMG is complex; patient symptoms, severity and trajectory can vary widely, and
early, sustained disease control is critical for improving patient-related outcomes.
The PREVAIL Phase III trial demonstrated the ability of gefurulimab to deliver rapid
and durable disease control starting as early as week one and lasting through one
year, with the added autonomy of once-weekly subcutaneous self-administration. This
approval provides an important new option for physicians and patients in the EU,
offering an effective and convenient approach to managing this severe, life-long
rare disease.”

> **Lutgarde Allard, President, European Myasthenia Gravis Association (EuMGFA),
> said:** “gMG is a disease marked by unique presentation, uncertainty, disruption
> and invisibility. For people across Europe living with this rare condition, the
> approval of this new medicine means more choice, convenience and the potential
> to regain independence in daily life. This news signifies more than scientific
> progress; it gives us hope and demonstrates that our community’s needs are being
> heard.”

> **Marc Dunoyer, Chief Executive Officer, Alexion, said**: “The approval of _Klygefa_
> in Europe marks an important milestone for the gMG community, introducing a first-
> of-its-kind treatment that combines the proven efficacy and safety of C5 inhibition
> with the flexibility of once-weekly, self-administered subcutaneous dosing. This
> novel dual-binding nanobody is a testament to Alexion’s pioneering legacy in complement
> science and commitment to developing differentiated therapies for people living
> with rare diseases.”

_Klygefa_ was generally well-tolerated, and the safety profile was consistent with
previous trials of C5 inhibitors eculizumab and ravulizumab in gMG.^(1)

The data from the PREVAIL trial were presented at the Myasthenia Gravis Foundation
of America (MGFA) Scientific Session during the American Association of Neuromuscular&
Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting and published in JAMA Neurology.
^(1)

_Klygefa_ is approved in the US, Japan and other countries for certain adults with
gMG. Regulatory submissions based on the PREVAIL results are under review in China
and additional countries.

Share on:
